MIRA INFORM REPORT

 

 

Report Date :           

24.02.2012

 

IDENTIFICATION DETAILS

 

Name :

TAPAZOL CHEMICAL WORKS LTD

 

 

Registered Office :

1 Hasolela Street, Western Industrial Zone, Beit Shemesh 99054  

 

 

Country :

Israel

 

 

Year of Establishment :

1931

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacturers, marketers and exporters of insecticides, fungicides, plant growth regulators and chemicals for the agriculture, public health and the veterinary fields

 

 

No. of Employees :

45

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 200,000

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30th, 2011

 

Country Name

Previous Rating

                   (30.06.2011)                  

Current Rating

(30.09.2011)

Israel

a2

a2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


Company name & address 

                                                                                            

TAPAZOL CHEMICAL WORKS LTD.

Telephone    972 2 992 60 40

Fax             972 2 992 60 50

1 Hasolela Street

Western Industrial Zone

BEIT SHEMESH                              99054        ISRAEL

 

 

HISTORY & LEGAL FORMATION

 

Originally established in 1931 as a non-registered firm.

 

Converted into a private limited company and registered as such as per file No. 51-049622-7 on the 09.04.1968.

 

 

SHARE CAPITAL

 

Authorized share capital NIS 1,000.00, divided into –

              10,000,000 ordinary shares of NIS 0.0001 each,

of which 6,000,000 shares amounting to NIS 600.00 were issued.

 

 

SHAREHOLDERS

 

1.    BIOVAC LTD., 50%, owned by Y. VACCINES LTD., owned by Arieh Nakash,

2.    The Harari family, 50%, owned by Izhak Harari (74%), Yaniv Harari (26%) and the Late Mrs. Genia Harari (holding 1 single share).

 

BIOVAC acquired 50% in subject in mid 2005.

 

 

DIRECTORS AND JOINT GENERAL MANAGERS

 

1.  Arieh Nakash,

2.  Izhak Harari.

 

 

BUSINESS

 

Manufacturers, marketers and exporters of insecticides, fungicides, plant growth regulators and chemicals for the agriculture, public health and the veterinary fields.

 

Also importers and marketers of veterinary medications, vaccines and public health products.

 

Most sales are to the local market (sales for export are insignificant).

 

Exports are to Eastern Europe, Africa and Latin America.

 

Subject’s clientele includes HAMASHBIR FOR AGRICULTURE, HAGARIN, HACHAKLAIT MUTUAL SOCIETY FOR CATTLE INSURANCE AND VETERINARY SERVICES, MEHADRIN, The Cotton Council, as well as Government Organizations and pet shops, hospitals and more.

 

Sole local representatives of:

SCHERING PLOUGH ANIMAL HEALTH (for veterinary products),

BIOKEMA, of Switzerland,

PRONDIL, of Uruguay.

 

Operating from rented premises (offices and plant), on an area of 2,350 sq. meters, in 1 Hasolela Street, Western Industrial Zone, Beit Shemesh, and from a rented branch, on an area of 150 sq. meters in Industrial Zone, Migdal Haemek.

 

Having 45 employees (had 40 employees in mid 2010).

Having 150 employees in the BIOVAC Group.

 

 

MEANS

 

Financial data not forthcoming.

 

There are 7 charges for unlimited amounts registered on the company’s assets (fixed assets, financial assets and vehicles), in favor of Bank Leumi Le’Israel Ltd. (last charge placed October 2007).

 

 

saleS

 

Sales figures not forthcoming.

 

 

OTHER COMPANIES

 

Also controlled by Arie Nakash:

 

BIOVAC LTD., manufacturers, exporters and marketers of vaccines and veterinary preparations, such as food essences, immunizations and drugs for poultry, ruminants, horses, fish, pets etc, ground disinfection products, etc.

 

GALFARMA PHARMACEUTICAL INDUSTRIES LTD., developers, manufacturers and marketers of pharmaceutical products in the veterinary as well as human fields, having 16 employees.


Y. VACCINES LTD.

 

ARPAL ALUMINIUM LTD., established in 1986, designers, manufacturers and marketers of aluminum systems for buildings, accessories for aluminum and glass systems for building envelopes and openings.

 

 

BANKERS

 

Bank Leumi Le’Israel Ltd., Central Branch (No. 800), Tel Aviv,  account No. 656200/00.

 

A check with the Central Banks’ database did not reveal any negative information concerning subject’s a/m bank account.

 

 

CHARACTER AND REPUTATION

 

In 2007, BAYER CROPSCIENCE AG filed a lawsuit against subject to the Tel Aviv District Court for violation of trade mark of pesticide, which subject allegedly is using with a similar brand name of the plaintiffs and contains similar materials.

 

In 2008 subject asked the Court to erase the complaint, but the Court refused and allowed the case to continue. No further data was found on this matter.

 

Apart of the above, nothing unfavorable learned.

 

Subject's officials refused to disclose financial data.

 

Subject is a very long established business.

 

Subject is ISO-9001:2008 certified.

 

Parent company BIOVAC is considered among the top 3 manufacturers and suppliers of veterinary vaccines in the local market.

 

The yearly value of veterinary drugs produced by local companies estimated in mid 2007 amounted to US$ 50 million, of which 50% were for export.

 

The local Chemical industry is considered one of the strongest in the market, with impressive growth trend in recent years. The chemical industry includes minerals extracted, refinery and petrochemical industry, manufacturing of pesticides for agriculture, pharmaceuticals and bio-technology industries, as well as other consumer products related industries, including paints, cosmetics, cleaning materials and others. The industry employs over 30,000 employees.

 

Total turnover of the local Chemical Industry in 2008 amounted to US$ 26 billion, comprising some 30% of Israel’s total industrial turnover. Sales for export recorded US$ 14 billion, comprising some 35% of Israel’s total export, continuing years of constant growth. Growth trend reversed in 2009, due to the economic crisis in the global markets. The Chemicals (incl. Pharmaceuticals) and Oil Refinery production in 2009 marked 7% decrease from 2008. Export of Industrial Chemicals plunged by 23.5% in 2009 from 2008, totaling US$10.4 billion.

The Chemical sector recovered in 2010, where export of Industrial Chemicals rose by 34.3% from 2009, reflecting the recovery in global markets, and kept the upward trend in 2011, reaching US$ 16.5 billion (of which US$ 7.3 billion were of pharmaceuticals), 18.6% up from 2010.

 

According to Central Bureau of Statistics data, investments in imported machinery and equipment from for the Chemical Industries (incl. Pharmaceuticals) in 2010 summed up to NIS 1,045 million, representing a 24.4% decrease in real terms from 2009 (after 0.5% decrease in 2009 from 2008 and 18.7% increase in 2008 from 2007).

 

 

SUMMARY

 

Notwithstanding the refusal to disclose financial details, considered good for trade engagements.

Maximum unsecured credit recommended US$ 200,000.

 

 

 

 

 


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.49.25

UK Pound

1

Rs.77.19

Euro

1

Rs.65.29

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.